These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 35614407)

  • 21. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
    Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
    J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.
    Yang H; Wen L; Zhao C; Chen J; Zhou Z; Zhou C; Cai L; Zhou C
    Heliyon; 2022 Dec; 8(12):e12374. PubMed ID: 36643302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.
    Xu Y; Hu M; Zhang M; Zhong W; Yin X; Sun Y; Chen M; Zhao J; Si X; Wang H; Zhang X; Zhang L; Li J; Guan H; Yang Z; Wang M
    Lung Cancer; 2018 Nov; 125():142-149. PubMed ID: 30429013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
    Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
    Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
    Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
    J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.
    Chiang CL; Lee CC; Huang HC; Wu CH; Yeh YC; Shen CI; Luo YH; Shiao TH; Chang HJ; Huang YT; Chen YM; Chou TY; Chiu CH
    Target Oncol; 2021 Mar; 16(2):207-214. PubMed ID: 33566300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    Ge M; Zhan Q; Zhang Z; Ji X; Zhou X; Huang R; Liang X
    BMC Cancer; 2019 Feb; 19(1):143. PubMed ID: 30755180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Yang H; Wen L; Zhao C; Li X; Shan C; Liu D; Hong W; Zhou Z; Zhou C; Cai L; Zhou C
    Front Oncol; 2022; 12():902664. PubMed ID: 35978803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
    Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
    J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of Clinicopathological Feature and Prognosis for 
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
    Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.
    Fan Y; Qin J; Han N; Lu H
    Ann Palliat Med; 2022 Apr; 11(4):1582-1588. PubMed ID: 34118831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.
    Oyoshi H; Hirata H; Hirano Y; Zenda S; Zhou Y; Tomizawa K; Fujisawa T; Nakamura M; Hojo H; Motegi A; Kageyama SI; Zenke Y; Goto K; Ishihara S; Naganawa S; Akimoto T
    Clin Exp Metastasis; 2023 Oct; 40(5):407-413. PubMed ID: 37468822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.